ofloxacin has been researched along with Bone Diseases, Infectious in 2 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Bone Diseases, Infectious: Bone diseases caused by pathogenic microorganisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Monte-Carlo simulations were used to evaluate the probability of target attainment (PTA) of different dosing regimens." | 1.62 | Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study. ( Arvieux, C; Bellissant, E; Comets, E; Fily, F; Foulquier, JB; Huten, D; Jullien, V; Laviolle, B; Lemaitre, F; Petitcollin, A; Polard, JL; Revest, M; Tattevin, P; Tron, C; Verdier, MC, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lemaitre, F | 1 |
| Fily, F | 1 |
| Foulquier, JB | 1 |
| Revest, M | 1 |
| Jullien, V | 1 |
| Petitcollin, A | 1 |
| Tattevin, P | 1 |
| Tron, C | 1 |
| Polard, JL | 1 |
| Verdier, MC | 1 |
| Comets, E | 1 |
| Huten, D | 1 |
| Arvieux, C | 1 |
| Bellissant, E | 1 |
| Laviolle, B | 1 |
| Legout, L | 1 |
| Senneville, E | 1 |
| Stern, R | 1 |
| Yazdanpanah, Y | 1 |
| Savage, C | 1 |
| Roussel-Delvalez, M | 1 |
| Rosele, B | 1 |
| Migaud, H | 1 |
| Mouton, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model[NCT02357407] | Phase 4 | 31 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for ofloxacin and Bone Diseases, Infectious
| Article | Year |
|---|---|
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases, Infectious; Female; Fluoroquin | 2021 |
Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases, Infectious; Cefepime; Cephalos | 2006 |